UB Paderborn / Katalog / Suche / in CDI

25 OPTIMIZED INFLIXIMAB MONOTHERAPY IS ASSOCIATED WITH BETTER HEALTHCARE UTILIZATION AND ENDOSCOPIC SCORES AND SIMILAR RATES OF INFLIXIMAB DISCONTINUATION WHEN COMPARED TO COMBINATION THERAPY

Gastroenterology (New York, N.Y. 1943), 2021-05, Vol.160 (6), p.S-6-S-6

2021

Volltextzugriff (PDF)

43/#512 Assessing robustness of an artificial intelligence derived histological biomarker across different sites of disease and in serial sections in tubo-ovarian high-grade serous carcinoma

International journal of gynecological cancer, 2022-12, Vol.32 (Suppl 3), p.A45-A46

2022

Volltextzugriff (PDF)

44/#219 Predicting response to platinum-based chemotherapy for tubo-ovarian high-grade serous carcinoma using an artificial intelligence histopathology platform

International journal of gynecological cancer, 2022-12, Vol.32 (Suppl 3), p.A46-A47

2022

Volltextzugriff (PDF)

Abstract A043: Validation of an artificial intelligence derived histological biomarker for gemcitabine response in resected pancreatic ductal adenocarcinoma (PDAC)

Cancer research (Chicago, Ill.), 2022-11, Vol.82 (22_Supplement), p.A043-A043

2022

Volltextzugriff (PDF)

Abstract P17: Effect of telemedicine adoption on accessibility and time to treatment in patients with thoracic malignancies during the COVID-19 pandemic

Clinical cancer research, 2021-03, Vol.27 (6_Supplement), p.P17-P17

2021

Volltextzugriff (PDF)

Biomarker Testing, Treatment Uptake, and Survival Among Patients With Urothelial Cancer Receiving Gene-Targeted Therapy

JAMA oncology, 2022-07, Vol.8 (7), p.1070

2022

Volltextzugriff (PDF)

Comprehensive integrated care for patients with sickle cell disease in a remote aboriginal tribal population in southern India

Pediatric blood & cancer, 2014-04, Vol.61 (4), p.702-705

2014

Volltextzugriff (PDF)

Development of an artificial intelligence-derived histologic signature associated with adjuvant gemcitabine treatment outcomes in pancreatic cancer

Cell reports. Medicine, 2023-04, Vol.4 (4), p.101013-101013, Article 101013

2023

Volltextzugriff (PDF)

Gamma-Glutamyltransferase 1 Promotes Clear Cell Renal Cell Carcinoma Initiation and Progression

Molecular cancer research, 2019-09, Vol.17 (9), p.1881-1892

2019

Volltextzugriff (PDF)

Gemcitabine response prediction in the adjuvant treatment of resected pancreatic ductal adenocarcinoma using an AI histopathology platform

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.e16295-e16295

2022

Volltextzugriff (PDF)

Impact of telemedicine adoption on accessibility and time to treatment in patients with thoracic malignancies during the COVID-19 pandemic

BMC cancer, 2021-10, Vol.21 (1), p.1-1094, Article 1094

2021

Volltextzugriff (PDF)

Medical employment growth, unemployment, and the opportunity cost of health care

International journal of health care finance and economics, 2016-12, Vol.16 (4), p.387-396

2016

Volltextzugriff (PDF)

Patient factors that drive unplanned acute care utilization in oncology care

Journal of clinical oncology, 2019-05, Vol.37 (15_suppl), p.e18011-e18011

2019

Volltextzugriff (PDF)

Perspectives on cancer care delivery from oncology patients who experienced unplanned acute care events

Journal of clinical oncology, 2019-09, Vol.37 (27_suppl), p.201-201

2019

Volltextzugriff (PDF)

Plasma Genotyping at the Time of Diagnostic Tissue Biopsy Decreases Time-to-Treatment in Patients With Advanced NSCLC—Results From a Prospective Pilot Study

JTO clinical and research reports, 2022-04, Vol.3 (4), p.100301-100301, Article 100301

2022

Volltextzugriff (PDF)

Primary endoscopic therapies for obesity and metabolic diseases

Current opinion in gastroenterology, 2015-09, Vol.31 (5), p.351-358

2015

Volltextzugriff (PDF)

Racial Differences in Cutaneous Events Among Patients Receiving Enfortumab Vedotin

Clinical genitourinary cancer, 2024-06, Vol.22 (3), p.102090-102090, Article 102090

2024

Volltextzugriff (PDF)

Racial Disparities in 30-Day Outcomes Following Index Admission for COVID-19

Frontiers in medicine, 2021-11, Vol.8, p.750650-750650

2021

Volltextzugriff (PDF)

S3320 Increase in National Inpatient Admissions for Inflammatory Bowel Disease: 2000-2014

The American journal of gastroenterology, 2021-10, Vol.116 (1), p.S1368-S1369

2021

Volltextzugriff (PDF)

S746 Infliximab Monotherapy Has Lower Rates of Treatment Discontinuation and Healthcare Utilization When Compared to Combination Therapy

The American journal of gastroenterology, 2021-10, Vol.116 (1), p.S343-S343

2021

Volltextzugriff (PDF)

S747 Increase in National Cost of Inpatient Inflammatory Bowel Disease Hospital Admissions Between 2000 and 2015

The American journal of gastroenterology, 2021-10, Vol.116 (1), p.S343-S344

2021

Volltextzugriff (PDF)

S895 Long-term Outcomes of High versus Low Anti-infliximab Antibody Titers in Patients with Crohn’s Disease: A Tertiary Referral Center Experience

The American journal of gastroenterology, 2021-10, Vol.116 (1), p.S421-S421

2021

Volltextzugriff (PDF)

Sa470 ASSOCIATIONS OF A COMPOSITE WEIGHTED MODEL PREDICTING INFLIXIMAB PERSISTENCE TO CLINICAL ENDPOINTS IN PATIENTS WITH CROHN'S DISEASE

Gastroenterology (New York, N.Y. 1943), 2021-05, Vol.160 (6), p.S-510-S-510

2021

Volltextzugriff (PDF)

Su441 PROACTIVE DRUG MONITORING OF INFLIXIMAB IS ASSOCIATED WITH BETTER HEALTHCARE UTILIZATION AND LOWER RATES OF INFLIXIMAB FAILURE IN CROHN'S PATIENTS

Gastroenterology (New York, N.Y. 1943), 2021-05, Vol.160 (6), p.S-691-S-692

2021

Volltextzugriff (PDF)

Treatments Administered to the First 9152 Reported Cases of COVID-19: A Systematic Review

Infectious diseases and therapy, 2020-09, Vol.9 (3), p.435-449

2020

Volltextzugriff (PDF)

Menü

Weitere Dienste

Einstellungen

25 OPTIMIZED INFLIXIMAB MONOTHERAPY IS ASSOCIATED WITH BETTER HEALTHCARE UTILIZATION AND ENDOSCOPIC SCORES AND SIMILAR RATES OF INFLIXIMAB DISCONTINUATION WHEN COMPARED TO COMBINATION THERAPY

43/#512 Assessing robustness of an artificial intelligence derived histological biomarker across different sites of disease and in serial sections in tubo-ovarian high-grade serous carcinoma

44/#219 Predicting response to platinum-based chemotherapy for tubo-ovarian high-grade serous carcinoma using an artificial intelligence histopathology platform

Abstract A043: Validation of an artificial intelligence derived histological biomarker for gemcitabine response in resected pancreatic ductal adenocarcinoma (PDAC)

Abstract P17: Effect of telemedicine adoption on accessibility and time to treatment in patients with thoracic malignancies during the COVID-19 pandemic

Biomarker Testing, Treatment Uptake, and Survival Among Patients With Urothelial Cancer Receiving Gene-Targeted Therapy

Comprehensive integrated care for patients with sickle cell disease in a remote aboriginal tribal population in southern India

Development of an artificial intelligence-derived histologic signature associated with adjuvant gemcitabine treatment outcomes in pancreatic cancer

Gamma-Glutamyltransferase 1 Promotes Clear Cell Renal Cell Carcinoma Initiation and Progression

Gemcitabine response prediction in the adjuvant treatment of resected pancreatic ductal adenocarcinoma using an AI histopathology platform

Impact of telemedicine adoption on accessibility and time to treatment in patients with thoracic malignancies during the COVID-19 pandemic

Medical employment growth, unemployment, and the opportunity cost of health care

Patient factors that drive unplanned acute care utilization in oncology care

Perspectives on cancer care delivery from oncology patients who experienced unplanned acute care events

Plasma Genotyping at the Time of Diagnostic Tissue Biopsy Decreases Time-to-Treatment in Patients With Advanced NSCLC—Results From a Prospective Pilot Study

Primary endoscopic therapies for obesity and metabolic diseases

Racial Differences in Cutaneous Events Among Patients Receiving Enfortumab Vedotin

Racial Disparities in 30-Day Outcomes Following Index Admission for COVID-19

S3320 Increase in National Inpatient Admissions for Inflammatory Bowel Disease: 2000-2014

S746 Infliximab Monotherapy Has Lower Rates of Treatment Discontinuation and Healthcare Utilization When Compared to Combination Therapy

S747 Increase in National Cost of Inpatient Inflammatory Bowel Disease Hospital Admissions Between 2000 and 2015

S895 Long-term Outcomes of High versus Low Anti-infliximab Antibody Titers in Patients with Crohn’s Disease: A Tertiary Referral Center Experience

Sa470 ASSOCIATIONS OF A COMPOSITE WEIGHTED MODEL PREDICTING INFLIXIMAB PERSISTENCE TO CLINICAL ENDPOINTS IN PATIENTS WITH CROHN'S DISEASE

Su441 PROACTIVE DRUG MONITORING OF INFLIXIMAB IS ASSOCIATED WITH BETTER HEALTHCARE UTILIZATION AND LOWER RATES OF INFLIXIMAB FAILURE IN CROHN'S PATIENTS

Treatments Administered to the First 9152 Reported Cases of COVID-19: A Systematic Review

Suchergebnisse filtern